MX341896B - Biomarcadores para el tratamiento de psoriasis. - Google Patents

Biomarcadores para el tratamiento de psoriasis.

Info

Publication number
MX341896B
MX341896B MX2012013803A MX2012013803A MX341896B MX 341896 B MX341896 B MX 341896B MX 2012013803 A MX2012013803 A MX 2012013803A MX 2012013803 A MX2012013803 A MX 2012013803A MX 341896 B MX341896 B MX 341896B
Authority
MX
Mexico
Prior art keywords
treatment
psoriasis
biomarkers
cell markers
predicting
Prior art date
Application number
MX2012013803A
Other languages
English (en)
Other versions
MX2012013803A (es
Inventor
H Schafer Peter
Lin Yong
Sutherland Donna
Original Assignee
Celgene Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp * filed Critical Celgene Corp *
Publication of MX2012013803A publication Critical patent/MX2012013803A/es
Publication of MX341896B publication Critical patent/MX341896B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención se refiere a un método de predecir si un paciente será responsivo a un tratamiento para psoriasis que comprende: cultivar una muestra biológica de células obtenidas de la piel del paciente en presencia o ausencia del compuesto de tratamiento; medir el nivel de un marcador celular seleccionado a partir de CD3, CD56, Foxp3, Langerin y una combinación de los mismos; y comparar el nivel del marcador celular en las células cultivadas en presencia del compuesto de tratamiento a aquél en las células cultivadas en ausencia del compuesto de tratamiento; en donde el compuesto de tratamiento es{2-[(1S)-1-(3-etoxi-4-metox ifenil)-2-metanosulfoniletil]-3-oxo-2,3-dihidro-1H-isoindol-4-il} -amida de ácido ciclopropanocarboxílico; y en donde un nivel disminuido del marcador celular en presencia del compuesto de tratamiento indica la probabilidad de una respuesta efectiva del paciente al compuesto de tratamiento. Figura 2.
MX2012013803A 2010-06-15 2011-06-15 Biomarcadores para el tratamiento de psoriasis. MX341896B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35511610P 2010-06-15 2010-06-15
US201161454916P 2011-03-21 2011-03-21
PCT/US2011/040430 WO2011159750A1 (en) 2010-06-15 2011-06-15 Biomarkers for the treatment of psoriasis

Publications (2)

Publication Number Publication Date
MX2012013803A MX2012013803A (es) 2012-12-17
MX341896B true MX341896B (es) 2016-09-07

Family

ID=44279738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013803A MX341896B (es) 2010-06-15 2011-06-15 Biomarcadores para el tratamiento de psoriasis.

Country Status (13)

Country Link
US (1) US20110318741A1 (es)
EP (1) EP2583098B1 (es)
JP (3) JP2013531499A (es)
KR (1) KR101913868B1 (es)
CN (1) CN103026229B (es)
AU (1) AU2011268450B2 (es)
BR (1) BR112012032217A2 (es)
CA (1) CA2798742A1 (es)
ES (1) ES2692152T3 (es)
IL (1) IL222844A (es)
MX (1) MX341896B (es)
NZ (1) NZ603375A (es)
WO (1) WO2011159750A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890548A1 (ru) 2010-11-04 2018-07-31 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к il-23
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
US20160077107A1 (en) * 2013-05-02 2016-03-17 Stichting Katholieke Universiteit Personalised medicine
WO2017091791A1 (en) * 2015-11-23 2017-06-01 Sirbal Ltd. Identification of biomarkers in serum samples collected from clinical trials by multiplex technology
US9994522B2 (en) 2014-05-11 2018-06-12 Mapi Pharma Ltd. Amorphous form of apremilast
WO2016014775A1 (en) * 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
CN107860830A (zh) * 2017-10-10 2018-03-30 暨南大学 一种寻常型银屑病血浆中生物标志物在其靶向药物的应用
WO2022015960A2 (en) * 2020-07-17 2022-01-20 Icahn School Of Medicine At Mount Sinai Biomarkers and classifier of psoriasis and methods of treatment

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE205542T1 (de) 1992-03-04 2001-09-15 Univ California Vergleichende genomhybridisierung
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
CA2262906C (en) 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
EP1035848B1 (en) 1997-07-31 2003-04-23 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf-alpha levels
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2001042507A1 (en) 1999-12-09 2001-06-14 Advanced Research & Technology Institute Fluorescent in situ rt-pcr
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
WO2003080048A1 (en) 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
BR0316256A (pt) 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
ZA200505308B (en) 2002-12-30 2006-10-25 Celgene Corp Fluoroalkoxy-substituted 1, 3-Dihydro-Isoindolyl compounds and their pharmaceutical uses
EP1603864A4 (en) 2003-03-05 2007-04-11 Celgene Corp DIPHENYLETHYLENE COMPOUNDS AND THEIR USE
ES2436606T3 (es) 2003-03-12 2014-01-03 Celgene Corporation Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
ES2362484T3 (es) 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20090270480A1 (en) * 2005-12-28 2009-10-29 Bernard Amegadzie Markers and Methods for Assessing and Treating Psoriasis and Related Disorders
JP5392089B2 (ja) * 2007-11-14 2014-01-22 三菱瓦斯化学株式会社 皮膚の乾癬予防または改善剤
CA2718412A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP2276483B1 (en) * 2008-03-27 2014-05-07 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2337799A2 (en) * 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases

Also Published As

Publication number Publication date
CA2798742A1 (en) 2011-12-22
JP2016185151A (ja) 2016-10-27
KR101913868B1 (ko) 2018-12-28
JP2013531499A (ja) 2013-08-08
MX2012013803A (es) 2012-12-17
AU2011268450B2 (en) 2015-07-16
WO2011159750A1 (en) 2011-12-22
CN103026229A (zh) 2013-04-03
ES2692152T3 (es) 2018-11-30
BR112012032217A2 (pt) 2016-10-25
US20110318741A1 (en) 2011-12-29
IL222844A0 (en) 2012-12-31
KR20130085953A (ko) 2013-07-30
EP2583098B1 (en) 2018-08-08
EP2583098A1 (en) 2013-04-24
JP2018183146A (ja) 2018-11-22
IL222844A (en) 2016-08-31
CN103026229B (zh) 2016-03-30
NZ603375A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
MX2012013803A (es) Biomarcadores para el tratamiento de psoriasis.
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX2018008324A (es) Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
EP2614369A4 (en) HEMMER OF HUMAN EZH2 AND METHOD FOR THEIR USE
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
EP2643350A4 (en) TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
EP2480669A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH FILAGRIN (FLG) BY MODULATION OF FLG EXPRESSION AND ACTIVITY
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
TN2012000450A1 (en) Biomarkers for mdm2 inhibitors for use in treating disease
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
EP2618881A4 (en) CATHETER ELECTRODE ASSEMBLIES AND METHODS OF CONSTRUCTING THESE ASSEMBLIES
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
IL245283B (en) Use of lysosomal acid lipase to treat lysosomal acid lipase deficiency in patients
IL212643A (en) Methods for predicting asparaginase activity in a patient and asparaginase for the treatment of aspartaginase-sensitive pathologies
BR112013004458A2 (pt) método e kit para detectar a presença de células que expressam he-4 em um indivíduo humano, e, método para o monitoramento de eficácia de tratamento de um paciente de câncer humano
MX2009011055A (es) Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos.
EP2400980A4 (en) VISFATINE THERAPEUTIC AGENTS FOR TREATING ACNE AND OTHER CONDITIONS
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
NZ609594A (en) Eph receptor expression in tumor stem cells
MX358726B (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
EP2589665A4 (en) METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND SET OF GENES AND KIT FOR USE IN THE METHOD
EP2635189A4 (en) PORTABLE DEVICE FOR EX-VIVO STIMULATION OF WHOLE BLOOD
MX2013012083A (es) Biomarcadores para el tratamiento de mieloma multiple.
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness

Legal Events

Date Code Title Description
FG Grant or registration